{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'Some of the central laboratory/analyte results which will not be reported to', 'investigators, site staff and participants are Hgb, hematocrit, reticulocyte count,', 'RBC count, etc. Additional details will be included in the SRM.', 'Table 8', 'Protocol Required Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Platelet count', 'RBC indices:', 'WBC count with Differential:', 'RBC count', 'MCV', 'Neutrophils', 'Reticulocyte count', 'MCH', 'Lymphocytes', 'Hematology', 'Hgb', 'MCHC', 'Monocytes', 'Hematocrit', 'RDW', 'Eosinophils', 'Basophils', 'Clinical', 'Sodium (serum)', 'AST', 'Carbon Dioxide (total)', 'Chemistry 1', 'Potassium (serum)', 'ALT', 'Albumin', 'Calcium (total and', 'Inorganic phosphate', 'Urea (serum)', 'albumin-adjusted)', 'Creatinine (serum)', 'Bilirubin (total and', 'Chloride (serum)', 'direct/indirect)', 'eGFR', 'Iron', 'Iron (serum)', 'Ferritin', 'UIBC', 'parameters', 'Hepcidin', 'TIBC', 'TSAT', 'Lipid', 'Total cholesterol', 'LDL-C (direct)', 'HDL-C', 'parameters', 'Other', 'Urine/serum hCG', 'FSH 4', 'Estradiol 4', 'laboratory', 'pregnancy test 2,3', 'tests', 'HemoCue Hgb', 'hsCRP', 'WBC, white blood cells; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean', 'corpuscular hemoglobin concentration; RDW, red blood cell distribution width, AST, aspartate transaminase; LDL-C,', 'low density lipoprotein-C; HDL-C, high density lipoprotein-C; TIBC, total iron binding capacity; hCG, human chorionic', 'gonadotropin; FSH, follicle-stimulating hormone.', '1.', 'Details of Liver Chemistry Stopping Criteria and Required Actions and Follow-Up Assessments after liver stopping', 'or monitoring event are given in Section 8.1.1 and Appendix 6.', '2.', 'For women of childbearing potential only.', '3.', 'Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC,', 'and for participants who transition to dialysis during the study.', '4.', 'Screening only. As needed for postmenopausal women when their menopausal status is in doubt. See Inclusion', 'Criteria Section 6.1.', '9.6.', 'Patient Reported Outcomes', 'The patient-reported effect of daprodustat and placebo on symptoms, health related', 'quality of life (HR-QoL), health status (e.g., utility) and work productivity and activity', 'impairment will be assessed. Symptoms will be assessed using a symptoms questionnaire', 'which is specific to anemia of Chronic Kidney Disease - Anemia Questionnaire (CKD-', 'AQ). Overall symptom severity will be assessed using the patient global impression of', 'severity (PGI-S), and overall symptom change using the patient global impression of', 'change (PGI-C). Quality of life will be measured via SF-36 and health status via the', 'EuroQol 5 Dimension 5 Level Health Utility Index (EQ-5D-5L) and the EuroQol Visual', '62']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Analogue Scale (EQ-VAS). Work productivity and regular daily activity impairment will', 'be measured via the Work Productivity and Activity Impairment Questionnaire for the', 'specific health problem of anemia, Clinical Practice Version 2.0 (WPAI-ANS- CPV;', 'V2.0).', 'All questionnaires used in this study have been translated and culturally adapted for use', 'in local country languages and will be administered electronically only. Specific', 'instructions on how the participant is to complete these questionnaires will be provided in', 'the SRM.', 'Patient reported outcomes questionnaires are to be administered at the beginning of the', 'visits and the subjects should not be told the results of any diagnostic tests prior to', 'completing the questionnaires. Adequate time must be allowed to complete all items on', 'questionnaires, and if necessary, the subject must be encouraged to complete any missing', 'items. So as to minimize the amount of missing data, the questionnaires should be', 'completed by participants at a clinic visit, in the order specified: PGI-S, PGI-C, CKD-', 'AQ, SF-36, EQ-5D-5L and EQ-VAS, then the WPAI-ANS- CPV. Additional instructions', 'on how investigators and site staff will be trained to provide participants with instructions', 'will be provided in the SRM.', '9.6.1.', 'Chronic Kidney Disease - Anemia Questionnaire (CKD-AQ)', 'A novel symptom questionnaire - CKD-AQ has been developed to collect concepts of', 'interest for the anemia of CKD population. Unlike the Functional Assessment of Cancer', 'Therapy - Anemia (FACT-AN) and Functional Assessment of Chronic Illness Therapy -', 'Fatigue (FACIT-Fatigue) which have not demonstrated content validity specific for the', 'anemia of CKD population, the novel CKD-AQ instrument was developed to verify and', 'ensure that concepts specific for anemia of CKD were captured and measured. It will', 'measure both the frequency and/or severity in anemia of CKD concepts such as', 'Weakness, Energy, Tiredness, Shortness of Breath, Exertion, Chest Pain, Memory,', 'Concentration, Standing, Sleep and Distress over the past 7 days.', '9.6.2.', 'Patient Global Impression of Severity (PGI-S) and Patient Global', 'Impression of Change (PGI-C)', \"The PGI-S is a 1-item questionnaire designed to assess participant's impression of\", 'disease severity of their anemia of CKD. It is measured on a 5-point disease severity', 'scale (absent, mild, moderate, severe, or very severe) during the past 24 hours.', \"The PGI-C is a 1-item questionnaire designed to assess a participant's impression of\", 'symptoms change of their anemia of CKD. It is measured on a 7-point Likert-type', 'response scale (very much improved, moderately improved, minimally improved, no', 'change, minimally worse, moderately worse, or very much worse) since they first started', 'the study.', '9.6.3.', 'Health Related Quality of Life (SF-36)', 'The SF-36 acute version is a general health status questionnaire designed to elucidate the', \"participant's self-perception of their health on several domains, including physical\", '63']\n\n###\n\n", "completion": "END"}